Severe Acute Respiratory Syndrome Coronavirus 2 Receptor Angiotensin Converting Enzyme 2 and Its Related Intervention Drugs
BIAN Jing-wei1,2, ZHAO Rong-sheng1, ZHAI Suo-di1, LI Zi-jian1,2*
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China; 2. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China
Abstract：The coronavirus disease 2019 (COVID-19) outbreak is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world, which has posed a great threat to global public health security. Angiotensin converting enzyme 2 (ACE2) has been identified as the major functional receptor of SARS-CoV-2, which plays an essential role in mediating virus invasion into host cells. Thus, an in-depth understanding of the recent progress of ACE2, its relationship with the virus and related drugs is of great significance for the prevention and treatment of COVID-19. Here, from the aspects of structure, expression and function, this article reviews the latest research progress of ACE2 and SARS-CoV-2. Meanwhile, this article also summarizes the mechanism of ACE2-mediated virus invasion and ACE2-related drugs, which will provide theoretical reference for viral prevention and treatment.
WORLD HEALTH ORGANIZATION. Coronavirus disease 2019 (COVID-19) Situation Report [EB/OL]. WHO, 2020. [2020-04-02]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
[2]
XU X, CHEN P, WANG J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020, 63(3):457-460
[3]
SU S, WONG G, SHI W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses[J]. Trends Microbiol, 2016, 24(6):490-502.
[4]
PEIRIS J S, LAI S T, POON L L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome[J]. Lancet, 2003, 361(9366):1319-1325.
[5]
OKBA N M, RAJ V S, HAAGMANS B L. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches[J]. Curr Opin Virol, 2017, 23: 49-58.
[6]
COUTARD B, VALLE C, DE LAMBALLERIE X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade[J]. Antiviral Res, 2020, 176: 104742.
[7]
LI F. Structure, function, and evolution of coronavirus spike proteins[J]. Annu Rev Virol, 2016, 3(1):237-261.
[8]
CRACKOWER M A, SARAO R, OUDIT G Y, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J].Nature, 2002, 417(6891):822-828.
[9]
WAN Y, SHANG J, GRAHAM R, et al. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS[J]. J Virol, 2020, 94 (7):e00127-20. DOI:10.1128/JVI.00127-20.
[10]
WRAPP D, WANG N, CORBETT K S,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367 (6483):1260-1263.
[11]
LAN J, GE J, YU J, et al. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor[J]. Nature, 2020, DOI: 10.1038/s41586-020-2180-5.
[12]
TIPNIS S R, HOOPER N M, HYDE R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase[J]. J Biol Chem, 2000, 275(43):33238-33243.
[13]
PAZ O M, RIQUELME J A, GARCIA L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease[J]. Nat Rev Cardiol, 2020, 17(2):116-129.
[14]
KUBA K, IMAI Y, PENNINGER J M. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases[J]. Circ J, 2013, 77(2):301-308.
[15]
DONOGHUE M, HSIEH F, BARONAS E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9[J]. Circ Res, 2000, 87(5):E1-9.
[16]
ZHANG H, WADA J, HIDA K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys[J]. J Biol Chem, 2001, 276(20):17132-17139.
[17]
YAN R, ZHANG Y, LI Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 [J]. Science, 2020, 367 (6485):1444-1448.
[18]
TIKELLIS C, JOHNSTON C I, FORBES J M, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy[J]. Hypertension, 2003, 41(3):392-397.
[19]
HAMMING I, TIMENS W, BULTHUIS M L, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2):631-637.
[20]
ZOU X, CHEN K, ZOU J, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection[J]. Front Med, 2020, DOI: 10.1007/s11684-020-0754-0.
[21]
HEURICH A, HOFMANN-WINKLER H, GIERER S, et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein[J]. J Virol, 2014, 88(2):1293-1307.
[22]
HOFFMANN M, KLEINE-WEBER H, SCHROEDER S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor[J]. Cell, 2020, DOI: 10.1016/j.cell.2020.02.052.
[23]
VICKERS C, HALES P, KAUSHIK V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase[J]. J Biol Chem, 2002, 277(17):14838- 14843.
[24]
SANTOS R, SAMPAIO W O, ALZAMORA A C, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)[J]. Physiol Rev, 2018, 98(1):505-553.
[25]
LI F, LI W, FARZAN M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309(5742):1864-1868.
[26]
KUBA K, IMAI Y, RAO S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med, 2005, 11(8):875-879.
[27]
INOUE Y, TANAKA N, TANAKA Y, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted[J]. J Virol, 2007, 81(16):8722-8729.
[28]
WANG H, YANG P, LIU K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway[J]. Cell Res, 2008, 18(2):290-301.
[29]
LIU Y, YANG Y, ZHANG C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[J]. Sci China Life Sci, 2020, DOI: 10.1360/SSV-2020-0037.
[30]
HUANG F, GUO J, ZOU Z, et al. Angiotensin Ⅱ plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients[J]. Nat Commun, 2014, 5(1):3595. DOI: 10.1038/ncomms4595.
[31]
ZOU Z, YAN Y, SHU Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections[J]. Nat Commun, 2014, 5(1):3594. DOI: 10.1038/ncomms4594.
[32]
CALDEIRA D, ALARCAO J, VAZ-CARNEIRO A, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and Meta-analysis[J]. BMJ, 2012, 345: e4260.
[33]
FERRARIO C M, JESSUP J, CHAPPELL M C, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin Ⅱ receptor blockers on cardiac angiotensin-converting enzyme 2[J]. Circulation, 2005, 111(20):2605-2010.
[34]
OCARANZA M P, GODOY I, JALIL J E, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat[J]. Hypertension, 2006, 48(4):572-578.
[35]
ISHIYAMA Y, GALLAGHER P E, AVERILL D B, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin Ⅱ receptors[J]. Hypertension, 2004, 43(5):970-976.
[36]
TIAN X, LI C, HUANG A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020, 9(1):382-385.
[37]
BHATTACHARYA M, SHARMA A R, PATRA P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach[J]. J Med Virol, 2020, DOI: 10.1002/jmv.25736.
[38]
LIU W, MORSE J S, LALONDE T, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV[J]. Chembiochem, 2020, 21(5):730-738.
[39]
VINCENT M J, BERGERON E, BENJANNET S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virol J, 2005, 2: 69, DOI: 10.1186/1743-422X-2-69.
[40]
COLSON P, ROLAIN J M, RAOULT D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2[J].Int J Antimicrob Agents, 2020: 105923, DOI: 10.1016/j.ijantimicag.2020.105923.
[41]
YAO X, YE F, ZHANG M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[J]. Clin Infect Dis, 2020, DOI: 10.1093/cid/ciaa237.
[42]
LIU J, CAO R, XU M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro[J]. Cell Discov, 2020, 6: 16, DOI: 10.1038/s41421-020-0156-0.
[43]
WANG M, CAO R, ZHANG L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020,30(3):269-271.
[44]
LI H, TAN X C, JIANG D, et al. Research progress in coronavirus and its therapeutic drugs[J]. Chin Pharm J(中国药学杂志), 2020, 55 (4):284-292.
[45]
ZHANG J S, MA X C, YU F, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV[J]. BioRxiv, 2020. DOI:10.1101/2020.02.05.935387.
[46]
SHEN L W, MAO H J, WU Y L, et al. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections[J]. Biochimie, 2017, 142: 1-10.
[47]
LUCAS J M, HEINLEIN C, KIM T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis[J]. Cancer Discov, 2014, 4(11):1310-1325.
2020, Vol. 55 
